HOPA News Articles
Clear filter
Late-Breaking HOPA News: The Evolving Landscape of NPM1-Mutated AML
Moh'd Mohanad A. Al-Dabet, PhD, AHI(AMT); Katia Al-Sawalha, BSc; and Olivia White, PharmD, BCOP, review revumenib and ziftomenib for NPM-1m disease and highlight key considerations when implementing these two therapies.
A Journey of a Thousand Miles Begins with a Single Step Navigating the Path to a Leadership Position
In this personal reflection from the latest issue of HOPA News, Mary Walters, PharmD, BCOP, and Peter Stuessy, PharmD, BCOP, compare and contrast their journeys into leadership roles - and what advice they would give others on their own leadership paths.
Late-Breaking HOPA News: Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer
Ming-Hei Tai, PharmD, BCOP, and Alexis Chapman, PharmD, BCOP, discuss the IMforte trial concerning lurbinectedin and atezolizumab in the treatment of extensive-stage small cell lung cancer.
Late-Breaking HOPA News: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma
Katelynn Granger, PharmD, BCOP, and Matthew Warrick, PharmD, BCPS, BCOP, dive into the emerging use of bispecific antibodies with chemotherapy in diffuse large B-cell lymphoma.
Late-Breaking HOPA News: Fam-trastuzumab deruxtecan-nxki for HER2 Ultralow Metastatic Breast Cancer
The ability of fam-trastuzumab deruxtecan-nxki to treat breast cancer patients with HER2 IHC 0 with positive membrane staining up to IHC 3+ has changed the treatment paradigm for metastatic disease.
